DOCSLIB.ORG

European Conference on Rare Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
European Conference on Rare Diseases EUROPEAN CONFERENCE ON RARE DISEASES Luxembourg 21-22 June 2005 EUROPEAN CONFERENCE ON RARE DISEASES Copyright 2005 © Eurordis For more information: www.eurordis.org Webcast of the conference and abstracts: www.rare-luxembourg2005.org TABLE OF CONTENT_3 ------------------------------------------------- ACKNOWLEDGEMENTS AND CREDITS A specialised clinic for Rare Diseases : the RD TABLE OF CONTENTS Outpatient’s Clinic (RDOC) in Italy …………… 48 ------------------------------------------------- ------------------------------------------------- 4 / RARE, BUT EXISTING The organisers particularly wish to thank ACKNOWLEDGEMENTS AND CREDITS 4.1 No code, no name, no existence …………… 49 ------------------------------------------------- the following persons/organisations/companies 4.2 Why do we need to code rare diseases? … 50 PROGRAMME COMMITTEE for their role : ------------------------------------------------- Members of the Programme Committee ……… 6 5 / RESEARCH AND CARE Conference Programme …………………………… 7 …… HER ROYAL HIGHNESS THE GRAND DUCHESS OF LUXEMBOURG Key features of the conference …………………… 12 5.1 Research for Rare Diseases in the EU 54 • Participants ……………………………………… 12 5.2 Fighting the fragmentation of research …… 55 A multi-disciplinary approach ………………… 55 THE EUROPEAN COMMISSION Funding of the conference ……………………… 14 Transfer of academic research towards • ------------------------------------------------- industrial development ………………………… 60 THE GOVERNEMENT OF LUXEMBOURG Speakers ……………………………………………… 16 Strengthening cooperation between academia • ------------------------------------------------- INTRODUCTION and industry ……………………………………… 62 THE CHAMBER OF COMMERCE OF LUXEMBOURG Researchers’ networks brought together by a Figures of rarity ……………………………………… 19 George Peters, Carine Radoux patients’ organisation …………………………… 64 Paradox of rarity ……………………………………… 20 • 5.3 Lessons learned from EU framework Diversity and heterogeneity of rare diseases …… 20 ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES AFM/TELETHON programmes for research …………………… 65 Common characteristics of rare diseases ……… 21 • 5.4 Research networks …………………………… 67 Clarification of some related concepts ………… 22 FOR EURORDIS : European integrated project on Rare diseases …………………………………… 22 Christel Nourissier, Project Leader spino-cerebellar ataxias (EUROSCA) ………… 67 Neglected diseases ……………………………… 22 Wilson Disease : Creating a European Clinical Yann Le Cam, Chief Executive Officer Fight for recognition ………………………………… 22 Database and designing randomised François Houÿez, Project Manager Rare diseases as a reality ……………………… 22 controlled clinical trials ………………………… 68 Patrice Régnier, Finance Officer ------------------------------------------------- EUGINDAT ……………………………………… 69 Flaminia Macchia, European Public Affairs Officer 1 / OVERTURE 5.5 Establishing networks in myology : William Gibon, Assistant 1.1 The word of the President of Eurordis ……… 2 4 Give more muscle to myology! ……………… 70 Media Contact : Stefan Chrobok and Aart van Iterson 1.2 The European Commission ………………… 26 5.6 Research and success stories ……………… 72 • 1.3 The Ministry of Health of Luxembourg …… 28 Clinical trials: research on specific domains / OUR PARTNERS ------------------------------------------------- pathologies, the ESCAPE trial ………………… 72 ALAN in Luxembourg, Alliance Maladies Rares, Agrenska, 2 / EPIDEMIOLOGY Rare Infectious Diseases that can be cured … 73 Federacion Espanola de Enfermedades Raras, Rare Diseases Denmark, 2.1 Rare diseases in numbers …………………… 30 Collecting and sharing tissue and DNA : Czech Agency for Drug Control, Orphanet and Eurocat 2.2 Rare cancers among rare diseases ………… 36 EuroBioBank ……………………………………… 74 Incidence of rare cancers Data collection for the European Network AFM, Prader Willi France, Psico Ballet, Een Häerz fir Kriibskrank Kanner in Granada (1998-2001) ………………………… 36 on Brain Dysmyelinating Diseases ENBDD …… 76 • ------------------------------------------------- 5.7 Collecting and sharing registry data ………… 78 THE MEMBERS OF THE PROGRAMME COMMITTEE 3 / DIAGNOSING RARE DISEASES: 5.8 Building a technology platform : • health care systems always challenged Centre National de Génotypage ……………… 80 AND ALL ECRD2005 PARTICIPANTS 3.1 EurordisCare2 : patients loose ------------------------------------------------- • confidence in health care systems ………… 39 6 / TREATMENT AND CARE THANKS TO 3.2 Primary immune-deficiency : 6.1 Targeting research to improve For the conference web site : a clear illustration of diagnosis delays …… 42 quality of life…………………………………… 82 Graphic Design : Baptiste Ferrier, Programming Php/MySql : Olf Software 3.3 A patient’s testimony …………………………… 43 Importance in making an accurate, simpler and Programming XHTML/CSS/WAI, integration, project management : Gravelet-Multimédia 3.4 A health care professional testimony ……… 44 easier diagnostic ……………………………… 82 3.5 How to improve diagnosis? ………………… 46 Therapeutic solutions that already exist Broadcast of the conference on the Internet : Prous Science A network to better diagnose X-Linked Mental for genetic diseases …………………………… 83 Deficiency ………………………………………… 46 6.2 A response to the needs Event organiser in Luxembourg: Meetincs SA, André Vasanne and Aurélia Lourenco A database to better diagnose Oro-Dental of the clinical trial community …………………8 7 Photographer : Harold Moreau anomalies………………………………………… 47 6.3 Treating with orphan drugs …………………… 91 4_ECRD 2005 REPORT PARTNERS_5 ------------------------------------------------ Status Report and Health benefits after ------------------------------------------------- -------------------------------- the epidemiologic surveillance of congenital 5 years of Orphan Drug legislation …………… 91 10 / TRAINING AND INFORMATION anomalies. Currently, forty registries in Official Support PARTNERS nineteen European countries survey more Treating with Orphan Drugs : 10.1 Best practice guidelines for care ------------------------------- than one million births per year. EUROCAT EUROPEAN Organisers / Partners an academic view ………………………………… 96 and management ……………………………… 152 is currently funded under the Public Health COMMISSION, Orphan Drug Regulation : views of a patient Help-lines and written Information …………… 152 Programme of the EC General Directorate for Public Health Programme, Health. The Central Registry is based at the DG Health and Consumer representative …………………………………… 100 10.2 Internet resources for the rare disease University of Ulster, UK. Protection Orphan Drug Regulation : community ……………………………………… 157 www.eurocat.ulster.ac.uk Programme of Community action in the field EURORDIS (European Organisation for views of an industry representative …………… 103 10.3 Training families and carers in Norway …… 160 of public health (2003-2008) Rare Diseases). The European Organisation The programme, meant to complement Availability of orphan medicinal products 10.4 The Agrenska Foundation : for Rare Diseases brings together 217 rare FEDER, Federación national policies, aims to protect human a family programme ……………………………16 3 disease patients’ organisations from 23 in Europe ………………………………………… 105 Española de Enfermedades health and improve public health. On 23 countries including fifteen EU member states. Views of a health care system : 10.5 Training on genetic medicine, new Raras, is a charity September 2002, the European Parliament It is one of the largest patients’ organisations The NICE approach to rare diseases ………… 111 technologies …………………………………… 165 organisation which and the Council adopted a new six-year in Europe. Eurordis’ objectives are to build a represents more than 90 Community action programme for public Views of a National Competent Authority : ------------------------------------------------- strong pan-European community of people rare diseases support groups in Spain. Since health. This programme runs from the 1st affected by rare diseases, to be their voice at The Italian Medicines Agency ………………… 114 11 / PATIENTS’ RIGHTS: mobility, 1999 Feder has carried out activities to of January 2003 to the 31st of December the European level, and to fight against the National measures / incentives for the research care in a foreign country. Decisions raise awareness on this health and social 2008. impact of rare diseases. and development of orphan products : of the European Court of Justice. public problem, to support these families and The new programme is based on three www.eurordis.org improve their quality of life. general objectives: information, rapid Spain …………………………………………… 115 11.1 Trans-border access to care : a view www.enfermedades-raras.org reaction to health threats and health ------------------------------------------------- from the European Court of Justice ……… 166 promotion through addressing health 7 / ACCESSING APPROPRIATE Rights to medical care abroad under EC ÅGRENSKA determinants. Activities such as networks, CENTRE is a CARE : organisation of care regulation ………………………………………… 167 co-ordinated responses, sharing of Swedish national ORPHANET is a European database that experience, training and dissemination of ------------------------------------------------- competence centre for rare disorders. It 7.1 Disability : are financial compensations deals with rare diseases and orphan drugs. information and knowledge will be provides programmes for children and young adapted to Rare Diseases? ………………… 117 12 / STRATEGIES FOR PREVENTION ORPHANET aims to improve the diagnosis, inter-linked and mutually reinforcing. people with disabilities, their families and 12.1
Load more

Recommended publications
  • ICD-10-CM Expert for SNF, IRF, and LTCH the Complete Official Code Set Codes Valid from October 1, 2018 Through September 30, 2019
    EXPERT 2019 ICD-10-CM Expert for SNF, IRF, and LTCH The complete official code set Codes valid from October 1, 2018 through September 30, 2019 Power up your coding optum360coding.com ITSN_ITSN19_CVR.indd 1 12/4/17 2:54 PM Contents Preface ................................................................................ iii ICD-10-CM Index to Diseases and Injuries .......................... 1 ICD-10-CM Official Preface ........................................................................iii Characteristics of ICD-10-CM ....................................................................iii ICD-10-CM Neoplasm Table ............................................ 331 What’s New for 2019 .......................................................... iv ICD-10-CM Table of Drugs and Chemicals ...................... 349 Official Updates ............................................................................................iv Proprietary Updates ...................................................................................vii ICD-10-CM Index to External Causes ............................... 397 Introduction ....................................................................... ix ICD-10-CM Tabular List of Diseases and Injuries ............ 433 History of ICD-10-CM .................................................................................ix Chapter 1. Certain Infectious and Parasitic Diseases (A00-B99) .........................................................................433 How to Use ICD-10-CM Expert for Skilled Nursing Chapter
    [Show full text]
  • Café Au Lait Spots As a Marker of Neuropaediatric Diseases
    Mini Review Open Access J Neurol Neurosurg Volume 3 Issue 5 - May 2017 DOI: 10.19080/OAJNN.2017.03.555622 Copyright © All rights are reserved by Francisco Carratalá-Marco Café Au Lait Spots as a Marker of Neuropaediatric Diseases Francisco Carratalá-Marco1*, Rosa María Ruiz-Miralles2, Patricia Andreo-Lillo1, Julia Dolores Miralles-Botella3, Lorena Pastor-Ferrándiz1 and Mercedes Juste-Ruiz2 1Neuropaediatric Unit, University Hospital of San Juan de Alicante, Spain 2Paediatric Department, University Hospital of San Juan de Alicante, Spain 3Dermatology Department, University Hospital of San Juan de Alicante, Spain Submission: March 22, 2017; Published: May 10, 2017 *Corresponding author: Francisco Carratalá-Marco, Neuropaediatric Unit, University Hospital of San Juan de Alicante, Spain, Tel: ; Email: Abstract Introduction: want to know in which The measure,Café au lait the spots presence (CALS) of isolated are shown CALS in representsthe normal a population risk factor forwithout neurological pathological disease. significance, although they could also be criteria for some neurologic syndromes. Unspecific association with general neurologic illnesses has been less frequently described. We Patients and methods: We set up an observational transversal study of cases, patients admitted for neuropaediatric reasons (NPP; n=49) excluding all the patients suffering from neurologic illnesses associated to CALS, and controls, a hospital simultaneously admitted pediatric population for non-neurologic causes (CP; n=101) since October 2012 to January 2013. The data were collected from the clinical reports at admission, and then analyzed by SPSS 22.0 statistical package, and the Stat Calc module of EpiInfo 7.0, following the ethics current rules of the institution for observational studies.
    [Show full text]
  • The National Economic Burden of Rare Disease Study February 2021
    Acknowledgements This study was sponsored by the EveryLife Foundation for Rare Diseases and made possible through the collaborative efforts of the national rare disease community and key stakeholders. The EveryLife Foundation thanks all those who shared their expertise and insights to provide invaluable input to the study including: the Lewin Group, the EveryLife Community Congress membership, the Technical Advisory Group for this study, leadership from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), the Undiagnosed Diseases Network (UDN), the Little Hercules Foundation, the Rare Disease Legislative Advocates (RDLA) Advisory Committee, SmithSolve, and our study funders. Most especially, we thank the members of our rare disease patient and caregiver community who participated in this effort and have helped to transform their lived experience into quantifiable data. LEWIN GROUP PROJECT STAFF Grace Yang, MPA, MA, Vice President Inna Cintina, PhD, Senior Consultant Matt Zhou, BS, Research Consultant Daniel Emont, MPH, Research Consultant Janice Lin, BS, Consultant Samuel Kallman, BA, BS, Research Consultant EVERYLIFE FOUNDATION PROJECT STAFF Annie Kennedy, BS, Chief of Policy and Advocacy Julia Jenkins, BA, Executive Director Jamie Sullivan, MPH, Director of Policy TECHNICAL ADVISORY GROUP Annie Kennedy, BS, Chief of Policy & Advocacy, EveryLife Foundation for Rare Diseases Anne Pariser, MD, Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health Elisabeth M. Oehrlein, PhD, MS, Senior Director, Research and Programs, National Health Council Christina Hartman, Senior Director of Advocacy, The Assistance Fund Kathleen Stratton, National Academies of Science, Engineering and Medicine (NASEM) Steve Silvestri, Director, Government Affairs, Neurocrine Biosciences Inc.
    [Show full text]
  • EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies
    Focusing on Personalised Medicine EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies Extended carrier screening is an important tool for prospective parents to help them determine their risk of having a child affected with a heritable disease. In many cases, parents aren’t aware they are carriers and have no family history due to the rarity of some diseases in the general population. What is covered by the screening? Genomics For Life offers a comprehensive Extended Carrier Screening test, providing prospective parents with the information they require when planning their pregnancy. Extended Carrier Screening has been shown to detect carriers who would not have been considered candidates for traditional risk- based screening. With a simple mouth swab collection, we are able to test for over 419 genes associated with inherited diseases, including Fragile X Syndrome, Cystic Fibrosis and Spinal Muscular Atrophy. The assay has been developed in conjunction with clinical molecular geneticists, and includes genes listed in the NIH Genetic Test Registry. For a list of genes and disorders covered, please see the reverse of this brochure. If your gene of interest is not covered on our Extended Carrier Screening panel, please contact our friendly team to assist you in finding a gene test panel that suits your needs. Why have Extended Carrier Screening? Extended Carrier Screening prior to pregnancy enables couples to learn about their reproductive risk and consider a complete range of reproductive options, including whether or not to become pregnant, whether to use advanced reproductive technologies, such as preimplantation genetic diagnosis, or to use donor gametes.
    [Show full text]
  • EFFECTIVE NEBRASKA DEPARTMENT of 01/01/2017 HEALTH and HUMAN SERVICES 173 NAC 1 I TITLE 173 COMMUNICABLE DISEASES CHAPTER 1
    EFFECTIVE NEBRASKA DEPARTMENT OF 01/01/2017 HEALTH AND HUMAN SERVICES 173 NAC 1 TITLE 173 COMMUNICABLE DISEASES CHAPTER 1 REPORTING AND CONTROL OF COMMUNICABLE DISEASES TABLE OF CONTENTS SECTION SUBJECT PAGE 1-001 SCOPE AND AUTHORITY 1 1-002 DEFINITIONS 1 1-003 WHO MUST REPORT 2 1-003.01 Healthcare Providers (Physicians and Hospitals) 2 1-003.01A Reporting by PA’s and APRN’s 2 1-003.01B Reporting by Laboratories in lieu of Physicians 3 1-003.01C Reporting by Healthcare Facilities in lieu of Physicians for 3 Healthcare Associated Infections (HAIs) 1-003.02 Laboratories 3 1-003.02A Electronic Ordering of Laboratory Tests 3 1-004 REPORTABLE DISEASES, POISONINGS, AND ORGANISMS: 3 LISTS AND FREQUENCY OF REPORTS 1-004.01 Immediate Reports 4 1-004.01A List of Diseases, Poisonings, and Organisms 4 1-004.01B Clusters, Outbreaks, or Unusual Events, Including Possible 5 Bioterroristic Attacks 1-004.02 Reports Within Seven Days – List of Reportable Diseases, 5 Poisonings, and Organisms 1-004.03 Reporting of Antimicrobial Susceptibility 8 1-004.04 New or Emerging Diseases and Other Syndromes and Exposures – 8 Reporting and Submissions 1-004.04A Criteria 8 1-004.04B Surveillance Mechanism 8 1-004.05 Sexually Transmitted Diseases 9 1-004.06 Healthcare Associated Infections 9 1-005 METHODS OF REPORTING 9 1-005.01 Health Care Providers 9 1-005.01A Immediate Reports of Diseases, Poisonings, and Organisms 9 1-005.01B Immediate Reports of Clusters, Outbreaks, or Unusual Events, 9 Including Possible Bioterroristic Attacks i EFFECTIVE NEBRASKA DEPARTMENT OF
    [Show full text]
  • Inherited Metabolic Disease
    Inherited metabolic disease Dr Neil W Hopper SRH Areas for discussion • Introduction to IEMs • Presentation • Initial treatment and investigation of IEMs • Hypoglycaemia • Hyperammonaemia • Other presentations • Management of intercurrent illness • Chronic management Inherited Metabolic Diseases • Result from a block to an essential pathway in the body's metabolism. • Huge number of conditions • All rare – very rare (except for one – 1:500) • Presentation can be non-specific so index of suspicion important • Mostly AR inheritance – ask about consanguinity Incidence (W. Midlands) • Amino acid disorders (excluding phenylketonuria) — 18.7 per 100,000 • Phenylketonuria — 8.1 per 100,000 • Organic acidemias — 12.6 per 100,000 • Urea cycle diseases — 4.5 per 100,000 • Glycogen storage diseases — 6.8 per 100,000 • Lysosomal storage diseases — 19.3 per 100,000 • Peroxisomal disorders — 7.4 per 100,000 • Mitochondrial diseases — 20.3 per 100,000 Pathophysiological classification • Disorders that result in toxic accumulation – Disorders of protein metabolism (eg, amino acidopathies, organic acidopathies, urea cycle defects) – Disorders of carbohydrate intolerance – Lysosomal storage disorders • Disorders of energy production, utilization – Fatty acid oxidation defects – Disorders of carbohydrate utilization, production (ie, glycogen storage disorders, disorders of gluconeogenesis and glycogenolysis) – Mitochondrial disorders – Peroxisomal disorders IMD presentations • ? IMD presentations • Screening – MCAD, PKU • Progressive unexplained neonatal
    [Show full text]
  • Amino Acid Disorders 105
    AMINO ACID DISORDERS 105 Massaro, A. S. (1995). Trypanosomiasis. In Guide to Clinical tions in biological fluids relatively easy. These Neurology (J. P. Mohrand and J. C. Gautier, Eds.), pp. 663– analyzers separate amino acids either by ion-ex- 667. Churchill Livingstone, New York. Nussenzweig, V., Sonntag, R., Biancalana, A., et al. (1953). Ac¸a˜o change chromatography or by high-pressure liquid de corantes tri-fenil-metaˆnicos sobre o Trypanosoma cruzi in chromatography. The results are plotted as a graph vitro: Emprego da violeta de genciana na profilaxia da (Fig. 1). The concentration of each amino acid can transmissa˜o da mole´stia de chagas por transfusa˜o de sangue. then be calculated from the size of the corresponding O Hospital (Rio de Janeiro) 44, 731–744. peak on the graph. Pagano, M. A., Segura, M. J., DiLorenzo, G. A., et al. (1999). Cerebral tumor-like American trypanosomiasis in Most amino acid disorders can be diagnosed by acquired immunodeficiency syndrome. Ann. Neurol. 45, measuring the concentrations of amino acids in 403–406. blood plasma; however, some disorders of amino Rassi, A., Trancesi, J., and Tranchesi, B. (1982). Doenc¸ade acid transport are more easily recognized through the Chagas. In Doenc¸as Infecciosas e Parasita´rias (R. Veroesi, Ed.), analysis of urine amino acids. Therefore, screening 7th ed., pp. 674–712. Guanabara Koogan, Sa˜o Paulo, Brazil. Spina-Franc¸a, A., and Mattosinho-Franc¸a, L. C. (1988). for amino acid disorders is best done using both South American trypanosomiasis (Chagas’ disease). In blood and urine specimens. Occasionally, analysis of Handbook of Clinical Neurology (P.
    [Show full text]
  • Federal Register/Vol. 69, No. 194/Thursday, October 7, 2004
    Federal Register / Vol. 69, No. 194 / Thursday, October 7, 2004 / Rules and Regulations 60083 Regulations Branch, Office of drawback requested on the drawback war are decided fairly, consistently, and Regulations and Rulings, U.S. Customs entry. This is determined as follows: based on all available medical and Border Protection. However, * * * * * information concerning the diseases personnel from other offices I 4. In § 191.171, a new paragraph (c) is associated with detention or internment participated in its development. added to read as follows: as a prisoner of war. DATES: List of Subjects in 19 CFR Part 191 This interim final rule is § 191.171 General; drawback allowance. effective October 7, 2004. Comments Claims, Commerce, CBP duties and * * * * * must be received on or before November inspection, Drawback. (c) Merchandise processing fees. In 8, 2004. cases where the requirements of Amendments to the Regulations ADDRESSES: Written comments may be paragraph (b)(1) of this section have submitted by: mail or hand-delivery to I For the reasons stated above, part 191 been met, merchandise processing fees Director, Regulations Management of the CBP Regulations (19 CFR part 191) will be eligible for drawback. (00REG1), Department of Veterans is amended as follows: Approved: October 4, 2004. Affairs, 810 Vermont Ave., NW., Room Robert C. Bonner, 1068, Washington, DC 20420; fax to PART 191 — DRAWBACK Commissioner, U.S. Customs and Border (202) 273–9026; e-mail to I 1. The general authority citation for Protection. [email protected]; or, through part 191 continues to read as follows: Timothy E. Skud, http://www.Regulations.gov. Comments Deputy Assistant Secretary of the Treasury.
    [Show full text]
  • Hereditary Gingival Fibromatosiswith Hemophilia B
    Vol. 17, No ?. UDC 616.311.2:616.151.5 CODEN: ASCRBK 1983 YU ISSN: 0001—7019 Original paper Hereditary gingival fibromatosis with hemophilia B Ilija Škrinjarić, Miljenko Bačić and Zvonko Poje Department of Children’s and Preventive Dentistry, Department of Periodontology and Department of Orthodontics, Faculty of Dentistry, University of Zagreb Received, February 7, 1983 Summary This work presents a case report of a generalized form of hereditary gin­ gival fibromatosis with hemophilia B as an accompanying disease. In the family of proband, consisting of 28 members, fibromatosis was present in 9 (4 males and 5 females). The pedigree analysis confirmed that gingival fibro­ matosis was transmited through three generations as an autosomal dominant trait. Neither proband, nor any other family member, showed other abnorma­ lities. Blood coagulation tests reveald hemophilia B (Christmas disease) in the proband. The coagulogram showed prolonged kaolin cephalin time (50 se­ conds) and low concentration of factor IX (F IX 18%). The case report sug­ gests that hemophilia B should be included in the list of diseases associated with gingival fibromatosis. Key words: gingival fibromatosis, hemophilia B Hereditary gingival fibromatosis manifests as an isolated trait, accompanied by other abnormalities or disease, or as a symptom of a specific syndrome. The most common clinical abnormalities associated with gingival fibromatosis are hypertrichosis, epilepsy, mental retardation, and defects of the eye, ear, nose, skeleton and nails (Fletcher1, Gorlin et a I.2, Jorgenson and Cocker3). Isolated gingival fibromatosis without other abnormalities is considered a special entity which differs from the fibromatosis accompanied by hypertrichosis, epilepsy or mental retardation (Cohen4).
    [Show full text]
  • Sema4 Noninvasive Prenatal Select
    Sema4 Noninvasive Prenatal Select Noninvasive prenatal testing with targeted genome counting 2 Autosomal trisomies 5 Trisomy 21 (Down syndrome) 6 Trisomy 18 (Edwards syndrome) 7 Trisomy 13 (Patau syndrome) 8 Trisomy 16 9 Trisomy 22 9 Trisomy 15 10 Sex chromosome aneuploidies 12 Monosomy X (Turner syndrome) 13 XXX (Trisomy X) 14 XXY (Klinefelter syndrome) 14 XYY 15 Microdeletions 17 22q11.2 deletion 18 1p36 deletion 20 4p16 deletion (Wolf-Hirschhorn syndrome) 20 5p15 deletion (Cri-du-chat syndrome) 22 15q11.2-q13 deletion (Angelman syndrome) 22 15q11.2-q13 deletion (Prader-Willi syndrome) 24 11q23 deletion (Jacobsen Syndrome) 25 8q24 deletion (Langer-Giedion syndrome) 26 Turnaround time 27 Specimen and shipping requirements 27 2 Noninvasive prenatal testing with targeted genome counting Sema4’s Noninvasive Prenatal Testing (NIPT)- Targeted Genome Counting analyzes genetic information of cell-free DNA (cfDNA) through a simple maternal blood draw to determine the risk for common aneuploidies, sex chromosomal abnormalities, and microdeletions, in addition to fetal gender, as early as nine weeks gestation. The test uses paired-end next-generation sequencing technology to provide higher depth across targeted regions. It also uses a laboratory-specific statistical model to help reduce false positive and false negative rates. The test can be offered to all women with singleton, twins and triplet pregnancies, including egg donor. The conditions offered are shown in below tables. For multiple gestation pregnancies, screening of three conditions
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • RD-Action Matchmaker – Summary of Disease Expertise Recorded Under
    Summary of disease expertise recorded via RD-ACTION Matchmaker under each Thematic Grouping and EURORDIS Members’ Thematic Grouping Thematic Reported expertise of those completing the EURORDIS Member perspectives on Grouping matchmaker under each heading Grouping RD Thematically Rare Bone Achondroplasia/Hypochondroplasia Achondroplasia Amelia skeletal dysplasia’s including Achondroplasia/Growth hormone cleidocranial dysostosis, arthrogryposis deficiency/MPS/Turner Brachydactyly chondrodysplasia punctate Fibrous dysplasia of bone Collagenopathy and oncologic disease such as Fibrodysplasia ossificans progressive Li-Fraumeni syndrome Osteogenesis imperfecta Congenital hand and fore-foot conditions Sterno Costo Clavicular Hyperostosis Disorders of Sex Development Duchenne Muscular Dystrophy Ehlers –Danlos syndrome Fibrodysplasia Ossificans Progressiva Growth disorders Hypoparathyroidism Hypophosphatemic rickets & Nutritional Rickets Hypophosphatasia Jeune’s syndrome Limb reduction defects Madelung disease Metabolic Osteoporosis Multiple Hereditary Exostoses Osteogenesis imperfecta Osteoporosis Paediatric Osteoporosis Paget’s disease Phocomelia Pseudohypoparathyroidism Radial dysplasia Skeletal dysplasia Thanatophoric dwarfism Ulna dysplasia Rare Cancer and Adrenocortical tumours Acute monoblastic leukaemia Tumours Carcinoid tumours Brain tumour Craniopharyngioma Colon cancer, familial nonpolyposis Embryonal tumours of CNS Craniopharyngioma Ependymoma Desmoid disease Epithelial thymic tumours in
    [Show full text]